Lit Matters 2: Ketamine Non-inferior to Morphine for Sickle Cell Pain

Vaso-occlusive crisis in sickle cell disease often means severe pain in patients who may already be opioid tolerant. Pain-dose ketamine appears non-inferior to morphine for 2-hour analgesia in acute sickle cell pain, while reducing total rescue opioid exposure.

Ketamine for Sickle Cell VOC Pain

• Noninferior 2-hour analgesia: A randomized double-blind trial found pain-dose ketamine matched morphine for pain relief at 2 hours in vaso-occlusive crisis, with end pain scores that were essentially identical.
• Lower cumulative opioid use: Ketamine reduced cumulative morphine milligram exposure despite similar pain control, a practical signal for opioid-tolerant sickle cell patients. We get into where that matters most in the episode.
• Adverse effect tradeoff: Dizziness, nausea, and vomiting were more common with ketamine, so the opioid-sparing benefit comes with a tolerability tradeoff rather than cleaner symptom control.
• Post nonopioid failure population: The trial enrolled sickle cell patients whose crisis pain persisted after IV or IM non-narcotic analgesics, making the comparison relevant to the ED escalation step rather than first touch.
• Operational reality in community EDs: Ketamine's main limitation may be logistics, since a 30-minute infusion and monitoring workflow can be harder to execute than morphine in smaller departments.